Sugammadex: Safety Profile and Adverse Effects in Infants Less Than Two Years of Age With Congenital Heart Disease
{{output}}
Background: Despite widespread clinical use and Food and Drug Administration (FDA) approval for use in patients from birth to < 2 years old in 2024, data regarding the safety and monitoring practices of sugammadex in infants with... ...
